First Patient Enrolled in Phase 1 Study of Midatech’s Panobinostat / HPBCD (MTX-110) for Recurrent Glioblastoma
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announced on 14 November
